Decoy Therapeutics Finalizes 1-for-12 Reverse Stock Split to Maintain Nasdaq Listing

summarizeSummary

Decoy Therapeutics Inc. has filed an amendment to its Certificate of Incorporation to effect a 1-for-12 reverse stock split, effective March 6, 2026, to meet Nasdaq's listing requirements.

check_boxKey Events

• Reverse Stock Split Finalized

  The company filed a Certificate of Amendment to its Certificate of Incorporation on March 5, 2026, to effect a 1-for-12 reverse stock split, becoming effective March 6, 2026.

• Nasdaq Compliance Objective

  The reverse split is intended to enable Decoy Therapeutics to regain compliance with The Nasdaq Capital Market's $1.00 minimum closing bid price requirement for continued listing.

• Trading on Split-Adjusted Basis

  Common Stock is expected to begin trading on a split-adjusted basis when Nasdaq opens on March 9, 2026, under a new CUSIP number.

• Share Structure Impact

  Every 12 shares of outstanding common stock will be combined into one, reducing the number of outstanding shares from approximately 6.38 million to 532,000. The number of authorized shares remains unchanged at 100 million.

auto_awesomeAnalysis

Decoy Therapeutics Inc. has officially implemented a 1-for-12 reverse stock split, a critical step to regain compliance with Nasdaq's minimum bid price requirement. This action follows the stockholder approval on February 24, 2026, and the Board's subsequent determination of the specific ratio. While necessary for continued listing, reverse stock splits are generally viewed negatively as they often indicate a company's struggle with a low stock price and do not fundamentally improve business operations or valuation. Investors should monitor the stock's performance post-split and the company's ability to sustain the higher price to avoid future compliance issues.